<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2017-06-23" updated="2019-12-02">
  <drugbank-id primary="true">DB13444</drugbank-id>
  <name>Ioxitalamic acid</name>
  <description>Ioxitalamate is an ionic iodinated contrast medium.[A27209] It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg.[A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995. Until the last review in 2015, this drug is still available in the market.[L1113]</description>
  <cas-number>28179-44-4</cas-number>
  <unii>967RDI7Z6K</unii>
  <average-mass>643.942</average-mass>
  <monoisotopic-mass>643.78021</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A27209</ref-id>
        <pubmed-id>23406968</pubmed-id>
        <citation>Kim KH, Kim YS, Kuh SU, Park HS, Park JY, Chin DK, Kim KS, Cho YE: Time- and dose-dependent cytotoxicities of ioxitalamate and indigocarmine in human nucleus pulposus cells. Spine J. 2013 May;13(5):564-71. doi: 10.1016/j.spinee.2013.01.019. Epub 2013 Feb  11.</citation>
      </article>
      <article>
        <ref-id>A33006</ref-id>
        <pubmed-id>19945959</pubmed-id>
        <citation>Hsu SP, Tsai TJ, Chien CT: Ioxitalamate induces renal tubular apoptosis via activation of renal efferent nerve-mediated adrenergic signaling, renin activity, and reactive oxygen species production in rats. Toxicol Sci. 2010 Mar;114(1):149-58. doi: 10.1093/toxsci/kfp290. Epub 2009 Nov 26.</citation>
      </article>
      <article>
        <ref-id>A33016</ref-id>
        <pubmed-id>23210836</pubmed-id>
        <citation>Lusic H, Grinstaff MW: X-ray-computed tomography contrast agents. Chem Rev. 2013 Mar 13;113(3):1641-66. doi: 10.1021/cr200358s. Epub 2012 Dec 5.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T196</ref-id>
        <isbn>978-3-642-46844-5</isbn>
        <citation>Buthiau D. and Khayat D. (1995). CT and MRI in oncology. Springer-Verlag.</citation>
      </textbook>
      <textbook>
        <ref-id>T53</ref-id>
        <isbn/>
        <citation>Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.</citation>
      </textbook>
      <textbook>
        <ref-id>T197</ref-id>
        <isbn>978-0-8138-1753-8</isbn>
        <citation>Coyne C. (2006). Comparative diagnostics pharmacology. Blackwell publishing.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L1113</ref-id>
        <title>Health Canada</title>
        <url>https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do</url>
      </link>
    </links>
    <attachments>
      <attachment>
        <ref-id>F54</ref-id>
        <title>Health Canada label</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/054/original/1.pdf?1525900564</url>
      </attachment>
      <attachment>
        <ref-id>F55</ref-id>
        <title>Telebrix Gastro monograph</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/055/original/1.pdf?1525902201</url>
      </attachment>
      <attachment>
        <ref-id>F56</ref-id>
        <title>Telebrix summary of product</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/056/original/1.pdf?1525905430</url>
      </attachment>
    </attachments>
  </general-references>
  <synthesis-reference/>
  <indication>Ioxitalamate in both of its available forms is indicated for exploration of the digestive tract by tomodensitometry or by regular gastroduodenal radiography. Its use is restrained to the cases in which the administration of barium sulfate is not recommended or contraindicated.[F55] The intravascular administration of ioxitalamate is contraindicated as it may present significant side effects.[F54]</indication>
  <pharmacodynamics>Ioxitalamate presents a very large osmolality which is related to the presence of renal toxicity, vasodilatation, bradycardia and pulmonary hypertension. This large osmolality allows ioxitalamate to move slowly in the bowel allowing for analysis for later follow excretion in the feces.[A33016]</pharmacodynamics>
  <mechanism-of-action>Ioxitalamate acts as a bowel opacifier which facilitates the interpretation of the anatomy and differentiation of bowel loops from soft tissue masses.[F54]</mechanism-of-action>
  <toxicity>Ioxitalamate is reported to induce acute kidney injury.[A33006] Preclinical studies showed that it does not present a teratogenic potential as well as a lack of effect on fertility.[F55] Ioxitalamate overdose may increase the risk of nephropathy and cardiovascular disorders.[F54]</toxicity>
  <metabolism>The rapid clearance suggests that ioxitalamate is not metabolized in the body.[T197]</metabolism>
  <absorption>When administered ioxitalamate is not absorbed in the GI tract. In the case of presence of an intestinal perforation, ioxitalamate is completely absorbed.[F55] When administered intravascularly, ioxitalamate is rapidly distributed in the interstitial space and intravascular compartment.[F56]</absorption>
  <half-life>The elimination half-life of ioxitalamate is 1.1 hours.[T56]</half-life>
  <protein-binding>Iodinated monomeric contrast agents are rarely bound to plasma proteins and when they bind, usually the association is very weak.[T196] When bound, it only represents from 0 to 27% of the ioxitalamate administered dose.[T53]</protein-binding>
  <route-of-elimination>As ioxitalamate is not absorbed in the normal intestine, the elimination route of this compound is entirely performed by the feces. When absorbed due to the presence of an intestinal perforation, ioxitalamate presents a rapid renal elimination.[F55] when ioxitalamate is administered intravascularly, it is eliminated unchanged mainly via renal excretion through glomerular filtration without reabsorption or tubular secretion. In the cases of renal failure, the elimination is mainly performed in the biliary, salivary, sudoral and colic route.[F56]</route-of-elimination>
  <volume-of-distribution>The volume of distribution of ioxitalamate is 194 ml/kg.[F56]</volume-of-distribution>
  <clearance>The total clearance rate of ioxitalamate is 120 ml/min.[F56]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as halobenzoic acids. These are benzoic acids carrying a halogen atom on the benzene ring.</description>
    <direct-parent>Halobenzoic acids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Benzoic acids and derivatives</subclass>
    <alternative-parent>1-carboxy-2-haloaromatic compounds</alternative-parent>
    <alternative-parent>2-halobenzoic acids</alternative-parent>
    <alternative-parent>4-halobenzoic acids</alternative-parent>
    <alternative-parent>Alkanolamines</alternative-parent>
    <alternative-parent>Aryl iodides</alternative-parent>
    <alternative-parent>Benzoic acids</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Carboximidic acids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Iodobenzenes</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organoiodides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Vinylogous halides</alternative-parent>
    <substituent>1-carboxy-2-haloaromatic compound</substituent>
    <substituent>2-halobenzoic acid</substituent>
    <substituent>2-halobenzoic acid or derivatives</substituent>
    <substituent>4-halobenzoic acid</substituent>
    <substituent>4-halobenzoic acid or derivatives</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Alkanolamine</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Aryl iodide</substituent>
    <substituent>Benzoic acid</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Carboximidic acid</substituent>
    <substituent>Carboximidic acid derivative</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Halobenzoic acid</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Iodobenzene</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organoiodide</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Vinylogous halide</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002569</drugbank-id>
      <name>Meglumine ioxitalamate</name>
      <unii>5791GC9HSW</unii>
      <cas-number>29288-99-1</cas-number>
      <inchikey>IFTFXKNYTWAOGK-WZTVWXICSA-N</inchikey>
      <average-mass>839.157</average-mass>
      <monoisotopic-mass>838.89088</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT002568</drugbank-id>
      <name>Sodium ioxitalamate</name>
      <unii>8P8Y8ZXJ8Y</unii>
      <cas-number>33954-26-6</cas-number>
      <inchikey>PZTAFRMXSAAHMQ-UHFFFAOYSA-M</inchikey>
      <average-mass>665.924</average-mass>
      <monoisotopic-mass>665.76215</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="spanish" coder="inn">acido ioxitalamico</synonym>
    <synonym language="english" coder="inn">Ioxitalamic acid</synonym>
  </synonyms>
  <products>
    <product>
      <name>Telebrix 38 Oral</name>
      <labeller>Liebel Flarsheim Company Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02131684</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Telebrix 38 Oral</name>
      <labeller>Liebel Flarsheim Company Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02131684</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Telebrix 38 Oral</name>
      <ingredients>Ioxitalamic acid + Ioxitalamic acid</ingredients>
    </mixture>
    <mixture>
      <name>Telebrix 38 Oral</name>
      <ingredients>Ioxitalamic acid + Ioxitalamic acid</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids, Carbocyclic</category>
      <mesh-id>D000146</mesh-id>
    </category>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Amino Sugars</category>
      <mesh-id>D000606</mesh-id>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Benzoates</category>
      <mesh-id>D001565</mesh-id>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Contrast Media</category>
      <mesh-id>D003287</mesh-id>
    </category>
    <category>
      <category>Diagnostic Uses of Chemicals</category>
      <mesh-id>D064907</mesh-id>
    </category>
    <category>
      <category>Hexosamines</category>
      <mesh-id>D006595</mesh-id>
    </category>
    <category>
      <category>Iodobenzoates</category>
      <mesh-id>D007463</mesh-id>
    </category>
    <category>
      <category>Sugar Alcohols</category>
      <mesh-id>D013402</mesh-id>
    </category>
    <category>
      <category>Triiodobenzoic Acids</category>
      <mesh-id>D014283</mesh-id>
    </category>
    <category>
      <category>Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media</category>
      <mesh-id/>
    </category>
    <category>
      <category>X-Ray Contrast Media, Iodinated</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V08AA05">
      <level code="V08AA">Watersoluble, nephrotropic, high osmolar X-ray contrast media</level>
      <level code="V08A">X-RAY CONTRAST MEDIA, IODINATED</level>
      <level code="V08">CONTRAST MEDIA</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB13444.pdf?1525906968</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.64</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.25e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>3-[(2-hydroxyethyl)-C-hydroxycarbonimidoyl]-5-[(1-hydroxyethylidene)amino]-2,4,6-triiodobenzoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>ioxitalamic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>643.942</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>643.78021</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(O)=NC1=C(I)C(C(O)=NCCO)=C(I)C(C(O)=O)=C1I</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H11I3N2O5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C12H11I3N2O5/c1-4(19)17-10-8(14)5(11(20)16-2-3-18)7(13)6(9(10)15)12(21)22/h18H,2-3H2,1H3,(H,16,20)(H,17,19)(H,21,22)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>OLAOYPRJVHUHCF-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>122.71</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>109.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>41.94</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>2.87</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>1.91</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Soluble</value>
      <source>Product Characteristics</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>349 ÂºC</value>
      <source>'MSDS'</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>1203</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>271</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>83517</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>31782</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Ioxitalamic_acid</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2107239</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>